| Completed | Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hema NCT02122081 | Sumithira Vasu | Phase 1 |
| Completed | Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT02299518 | Alice Mims | Phase 1 |
| Completed | Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute NCT02316964 | Sumithira Vasu | Phase 1 |
| Terminated | Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML NCT01849276 | Northwestern University | Phase 1 |
| Terminated | MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloi NCT02049801 | Bruno C. Medeiros | Phase 1 |
| Unknown | Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Ch NCT02071901 | Case Comprehensive Cancer Center | Phase 2 |
| Terminated | Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute My NCT02029417 | Roswell Park Cancer Institute | Phase 2 |
| Active Not Recruiting | Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or NCT02094794 | City of Hope Medical Center | Phase 2 |
| Terminated | Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT02030405 | Steven E. Coutre | Phase 2 |
| Completed | CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome NCT02019069 | Rondeep Brar | Phase 2 |
| Terminated | AML Therapy With Irradiated Allogeneic Cells NCT02105116 | Rutgers, The State University of New Jersey | N/A |
| Terminated | Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leuke NCT01904643 | Stanford University | Phase 1 |
| Withdrawn | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Maligna NCT01652014 | University of Medicine and Dentistry of New Jersey | Phase 2 |
| Completed | AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia NCT01798901 | Alison Walker | Phase 1 |
| Terminated | Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia NCT01876953 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Completed | Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay NCT01872819 | University of Washington | N/A |
| Completed | Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukem NCT01869114 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Le NCT01869777 | Wake Forest University Health Sciences | N/A |
| Completed | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hemato NCT01789255 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treatin NCT01707004 | University of Wisconsin, Madison | Phase 2 |
| Completed | Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodyspla NCT01831232 | Fred Hutchinson Cancer Center | N/A |
| Withdrawn | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT01835288 | Stanford University | Phase 2 |
| Completed | Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT01820624 | Paolo Caimi, MD | Phase 1 |
| Completed | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01839916 | University of Chicago | Phase 2 |
| Completed | Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia NCT01822015 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | EARLY_Phase 1 |
| Terminated | Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia NCT01801046 | University of Southern California | Phase 1 |
| Completed | CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Mye NCT01768897 | Wake Forest University Health Sciences | Phase 1 |
| Completed | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing NCT01588015 | City of Hope Medical Center | Phase 1 |
| Completed | Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With NCT01519596 | Wake Forest University Health Sciences | N/A |
| Terminated | Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS NCT01607645 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leuk NCT01839240 | University of Chicago | Phase 1 |
| Withdrawn | Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia NCT01548911 | Wake Forest University Health Sciences | Phase 2 |
| Terminated | Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT01550185 | Roswell Park Cancer Institute | Phase 1 |
| Withdrawn | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant NCT01558778 | Roswell Park Cancer Institute | N/A |
| Completed | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem NCT01529827 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies NCT01523223 | Robert Lowsky | Phase 1 |
| Completed | Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission NCT01842139 | University of Chicago | Phase 1 |
| Terminated | Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy NCT01521936 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia NCT01555268 | Roswell Park Cancer Institute | Phase 1 |
| Terminated | Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies NCT01564277 | Roswell Park Cancer Institute | Phase 2 |
| Completed | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies NCT01384513 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Terminated | Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed NCT01342887 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating NCT01349972 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT01246622 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Old NCT02085408 | ECOG-ACRIN Cancer Research Group | Phase 3 |
| Completed | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies NCT01273766 | Wake Forest University Health Sciences | Phase 2 |
| Active Not Recruiting | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic NCT01199562 | City of Hope Medical Center | — |
| Completed | Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previ NCT01235572 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT01253447 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS NCT01141725 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Tran NCT01233921 | Martin, Paul | N/A |
| Completed | Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematolo NCT01175785 | Nohla Therapeutics, Inc. | Phase 2 |
| Completed | Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Adva NCT01101880 | University of Washington | Phase 2 |
| Completed | Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia NCT01174888 | Alison Walker | Phase 1 |
| Completed | Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia NCT01127009 | Case Comprehensive Cancer Center | Phase 1 |
| Terminated | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload NCT01159067 | City of Hope Medical Center | Phase 2 |
| Terminated | Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory NCT01159301 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Bloo NCT01076270 | Fred Hutchinson Cancer Center | N/A |
| Completed | Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or A NCT01083706 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Pr NCT01031368 | Nohla Therapeutics, Inc. | Phase 1 |
| Completed | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy NCT00890747 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML NCT00895934 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Pa NCT00860574 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease NCT00863434 | University of Washington | Phase 2 |
| Completed | Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With NCT00856388 | Roswell Park Cancer Institute | N/A |
| Completed | Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia NCT02144675 | Rutgers, The State University of New Jersey | Phase 2 |
| Completed | Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS NCT00839982 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia NCT00795002 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory A NCT00634244 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Le NCT00742625 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant NCT00795769 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors NCT00799461 | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | Phase 3 |
| Completed | Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia NCT00703300 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High- NCT00475150 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukem NCT00673153 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid L NCT00602771 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT00602225 | University of Washington | Phase 1 / Phase 2 |
| Terminated | Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treat NCT00540995 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Completed | Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia NCT00492401 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem NCT00489203 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myelo NCT00462605 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia NCT00470197 | National Cancer Institute (NCI) | Phase 1 |
| Completed | GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplast NCT00459212 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, NCT00445744 | Fred Hutchinson Cancer Center | N/A |
| Completed | Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia NCT00407966 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Sunitinib in Treating Patients With Idiopathic Myelofibrosis NCT00387426 | National Cancer Institute (NCI) | Phase 2 |
| Completed | High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in T NCT00536601 | Roswell Park Cancer Institute | N/A |
| Completed | Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer NCT00357708 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem NCT00408681 | Fred Hutchinson Cancer Center | N/A |
| Completed | Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia NCT00352365 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or M NCT00357305 | National Cancer Institute (NCI) | Phase 1 |
| Completed | PXD101 in Treating Patients With Acute Myeloid Leukemia NCT00357032 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Bloo NCT00343798 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrom NCT00331513 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgki NCT00275080 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With NCT00322101 | Fred Hutchinson Cancer Center | Phase 3 |
| Completed | Vorinostat in Treating Patients With Acute Myeloid Leukemia NCT00305773 | National Cancer Institute (NCI) | Phase 2 |
| Completed | 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic NCT00301938 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Ph NCT00301769 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemi NCT00131989 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hemat NCT00103272 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia NCT00112853 | National Cancer Institute (NCI) | Phase 1 |
| Completed | SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic NCT00098826 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lym NCT00098423 | National Cancer Institute (NCI) | Phase 1 |
| Completed | XK469R in Treating Patients With Refractory Hematologic Cancer NCT00095797 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT00101296 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leuk NCT00101231 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or NCT00096122 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Tran NCT01056614 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia NCT00093418 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic S NCT00087204 | National Cancer Institute (NCI) | Phase 1 |
| Completed | CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, NCT00084916 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone To NCT00089011 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previo NCT00079378 | National Cancer Institute (NCI) | Phase 1 |
| Completed | 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies NCT00077181 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Ac NCT00085124 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Mali NCT00078858 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia NCT00070551 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Trans NCT00119366 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT00062075 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer NCT00060372 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia NCT00049582 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leuke NCT00052520 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Le NCT00052598 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete NCT00045396 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia NCT00039117 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary A NCT00045435 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leuke NCT00039091 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer NCT00049504 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation NCT00040846 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia NCT00027872 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer NCT00012376 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Imm NCT00014235 | Fred Hutchinson Cancer Center | N/A |
| Completed | Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 i NCT00006363 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in NCT00093743 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients Wi NCT00005799 | Fred Hutchinson Cancer Center | N/A |
| Completed | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenola NCT00112593 | Fred Hutchinson Cancer Center | N/A |
| Completed | Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patie NCT00005940 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed NCT00008177 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloi NCT00003190 | National Cancer Institute (NCI) | Phase 3 |
| Completed | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patient NCT01177371 | Case Comprehensive Cancer Center | Phase 2 |
| Approved For Marketing | Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyel NCT01869803 | Wake Forest University Health Sciences | — |